Valuation: Sutro Biopharma, Inc.

Capitalization 493M 418M 385M 363M 678M 45.97B 688M 4.52B 1.77B 22.07B 1.85B 1.81B 78.37B P/E ratio 2026 *
-3.7x
P/E ratio 2027 * -3.88x
Enterprise value 340M 288M 266M 250M 467M 31.69B 475M 3.11B 1.22B 15.22B 1.28B 1.25B 54.03B EV / Sales 2026 *
9.62x
EV / Sales 2027 * 9.61x
Free-Float
99.04%
Yield 2026 *
-
Yield 2027 * -
1 day+3.44%
1 week+10.06%
Current month+19.51%
1 month+28.99%
3 months+127.77%
6 months+281.67%
Current year+157.30%
1 week 24.94
Extreme 24.9446
30.5
1 month 19.11
Extreme 19.11
30.5
Current year 10.15
Extreme 10.15
30.5
1 year 5.23
Extreme 5.231
30.5
3 years 5.23
Extreme 5.231
61.3
5 years 5.23
Extreme 5.231
237
10 years 5.23
Extreme 5.231
283
Manager TitleAgeSince
Chief Executive Officer 55 2025-03-12
Director of Finance/CFO 53 2025-06-01
Chief Tech/Sci/R&D Officer 64 2023-04-30
Director TitleAgeSince
Director/Board Member 70 2009-07-31
Director/Board Member 67 2017-01-31
Director/Board Member 51 2018-07-24
Change 5d. change 1-year change 3-years change Capi.($)
+3.44%+10.06%+413.72%-32.34% 493M
+0.51%+5.47%+36.34%+102.50% 52.12B
+0.26%+2.98%+103.18%+24.51% 47.25B
-4.34%-8.39%+106.47%+776.06% 31.67B
+1.08%+8.03%+0.47%-23.28% 25.15B
+0.49%+4.61%+84.06%-31.28% 19.54B
+0.61%+2.55%+43.13%-36.37% 17.83B
+1.09%+9.96%+78.02%+240.57% 17.33B
+1.29%+12.28%-14.22%+1,245.22% 16.38B
+0.58%+7.58%+80.62% - 15.45B
Average +0.44%+5.02%+93.18%+251.73% 24.32B
Weighted average by Cap. -0.06%+3.51%+62.22%+236.12%

Financials

2026 *2027 *
Net sales 35.36M 29.95M 27.62M 26.05M 48.58M 3.3B 49.36M 324M 127M 1.58B 133M 130M 5.62B 24.87M 21.06M 19.42M 18.32M 34.16M 2.32B 34.71M 228M 89.17M 1.11B 93.29M 91.34M 3.95B
Net income -144M -122M -113M -106M -198M -13.45B -201M -1.32B -518M -6.46B -542M -530M -22.93B -140M -119M -110M -103M -193M -13.07B -196M -1.28B -503M -6.28B -526M -515M -22.29B
Net Debt -153M -130M -120M -113M -210M -14.28B -214M -1.4B -549M -6.86B -575M -563M -24.34B -254M -215M -199M -187M -349M -23.69B -355M -2.33B -912M -11.38B -954M -934M -40.39B
Logo Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Employees
137
Date Price Change Volume
26-04-15 29.77 $ +3.44% 315,556
26-04-14 28.78 $ +9.89% 509,731
26-04-13 26.19 $ +1.28% 391,289
26-04-10 25.86 $ -3.36% 202,130
26-04-09 26.76 $ -1.07% 186,431
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
29.77USD
Average target price
30.11USD
Spread / Average Target
+1.15%

Quarterly revenue - Rate of surprise